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Abstract
The period toward the end of patients’ participation in late stage blinded clinical trials is highly resource intensive
for the sponsor. Consider first a Phase 3 trial. If the trial is a success, the sponsor has to implement the next steps,
which might be filing for approval of the drug with the US Food and Drug Administration (FDA). To shorten the
time interval between trial completion and submission of the package to the FDA, sponsors front-load as much
work as is possible at risk. The approach is efficient if the trial succeeds but is inefficient if it fails. For a failed trial,
the sponsor is unlikely to proceed with the plan that assumed success. Phase 2 trials are also at risk of being
inefficient. Many activities, such as planning for drug interaction studies, thorough QT studies, or site selection for
Phase 3 trials, are set in motion prior to completion of the Phase 2 trial. The work going on in parallel is wasted if
the trial fails. The proposal to improve the efficiency is to let an independent entity provide the sponsor critical
information at an earlier time necessary to reevaluate activities ongoing in parallel and external to the trial.
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Background
The timelines for achieving certain milestones following
the completion of a Phase 2 or 3 randomized, double-
blind clinical trial are very aggressive, as the stakes are
high. The practice in industry is to compress the time be-
tween the release of results and the next step, assuming a
successful trial. The next step for a Phase 3 trial might be
submitting a New Drug Application (NDA) to a health
agency such as the US Food and Drug Administration
(FDA). Or it might mean concurrently planning for trials
in a different age range or in related indications. For a
Phase 2 trial, the next step might be any combination of
the following activities: identifying sites for a global Phase
3 trial, planning and conducting a thorough QT study and
drug interaction studies, or preparing to meet with health
authorities (known as an End of Phase 2 [EOP2] meeting)
to clarify aspects of the sponsor’s drug development plan.
Compression of timelines is achieved by front-loading the
tasks while the Phase 2 or 3 trial is still ongoing. The effort
is undertaken at risk, and is of necessity highly labor inten-
sive. Front-loading is a highly coordinated activity. Various
functions within the sponsor’s organization — project
management, commercial operations, manufacturing, drug
safety, biostatistics, clinical, clinical operations, data man-
agement, statistical programming, regulatory, medical writ-
ing — all work in lockstep, while the trial is still blinded, to
complete their tasks in a timely manner.
Front-loading pays off for a successful trial but it is
inefficient if the trial fails. Lack of attention to other
development areas exacerbates the inefficiency. Some
examples of at-risk work that may become unnecessary
if the trial fails include preparation of documents for
submission to regulatory agencies or initiating steps to
plan additional trials. The purpose of this article is to
propose a way to improve the process by providing the
sponsor limited but important information at an earlier
time to reduce the risk of wasting resources.
To understand the proposal, it is helpful to outline
the sequence of steps after the last patient is enrolled.
After completion of enrollment, patients are followed
until their last visit. Before and after completion of en-
rollment, data are collected, entered in the database,
and “cleaned” (i.e., checked for errors and logical
consistency). Different data elements follow their own
cadence from data capture to availability in the data-
base. Some data elements are available sooner than
others; however, the standard practice requires all data
to be fully available in the database prior to its lock.Correspondence: jganju@globalbloodtx.com
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The different data elements fall into the following
broad categories:
– Safety data, which come from different sources
including reports of adverse events by the
investigators, results from central and local
laboratories, and electrocardiograms
– Efficacy data on the primary and secondary
endpoints, which also come from different sources.
Examples include: patient-reported outcomes (e.g.,
disability index, quality of life questionnaires),
assessment made by the patient’s site staff (e.g., signs
and symptoms), and adjudicated endpoints (e.g.,
stroke or myocardial infarction)
– Other data such as medical history, demographics,
and concomitant medications
After the database is locked, the study is unblinded. By
unblinding after database lock, we mean the release of
unblinded study results. The time interval between avail-
ability of almost all or all data and unblinding varies by
therapeutic area and other factors, ranging from one
month to several months.
The proposal to improve the operational efficiency will
benefit trials with a large time window between data
availability and unblinding. An example of such a trial is
a global, endpoint-adjudicated, event-driven trial. Event-
driven trials have a common closure date; that is, the
final visit is approximately the same for all trial patients
in calendar time. The final visit occurs after accrual of
the requisite number of events and achieving of the
protocol-stipulated minimum trial size and minimum
duration of follow-up. Projecting when the final visit will
occur helps to determine the final visit date. Estimating
the timing of the final event and arranging for (approxi-
mately) the same final visit date across all global sites is
complex and takes time to execute. Further, the end-
point information provided by non-English speaking
sites has to be translated into English and then sent to
an endpoints committee who meet at scheduled times to
determine the absence or occurrence of an event. These
steps usually mean that the time window between avail-
ability of almost all the data on the endpoint and data-
base lock is large.
What information to release to the sponsor, the
timing, and the benefit are explained next.
Main text
The information given the sponsor
What information must the sponsor receive? The rec-
ommendation is a restricted version of the result on
the primary efficacy endpoint, such as whether a cer-
tain condition is met. The condition proposed is if the
p value for the primary endpoint, denoted p, exceeds a
certain prespecified threshold p1. The actual value of p is
not provided. All the sponsor is told is whether p > p1. We
call this the “high level analysis.” The method of analysis
to calculate p is the same as the one described in the stat-
istical analysis plan.
The choice of p1 is important. The idea is to select a
value such that if p > p1, it is understood that the trial has
failed with respect to the primary endpoint. p1 should be
large enough that p ≤ p1 does not suggest success but not
so large that the probability p > p1 is low under the null. A
value of p1 in the range of 0.20—0.30 seems reasonable.
For example, suppose we choose p1 = 0.25. p > 0.25
means a negative result on the primary endpoint,
whereas p ≤ 0.25 does not imply success.
An independent entity external to the sponsor can
undertake the task of performing the analysis and pro-
vide the information to the sponsor. Most Phase 3 and
many Phase 2 trials have data monitoring committees
(DMCs) to monitor the safety and efficacy. If agreeable
to the DMC, they can relay the necessary information to
the sponsor. To maintain trial integrity, the burden is on
the sponsor to document all steps, including who within
the sponsor’s organization will receive the result, and to
make the process transparent. A choice of p1 that is
small (e.g., 0.10) is not advisable because of the risk it poses
to the integrity of the trial. A result that p ≤ p1 = 0.10 may
be interpreted as a successful trial even though the results
on secondary endpoints (some perhaps as important as the
primary endpoint) and the risk-benefit assessment are still
pending. To be informed that the chance of success has
increased because p ≤ p1, when the sponsor is already
working at risk assuming a successful trial, is not
necessary. It raises suspicion because the sponsor is
given information that ought not to matter.
Timing of analysis including release of result to sponsor
The sponsor should receive the result (i.e., whether p > p1)
late in the course of the blinded trial. Late means that no
changes can be made to the trial itself, but knowing the
result allows for affecting parallel activities external to the
trial. This suggests a time close to the availability of all
data for analysis of the primary endpoint. Conducting the
analysis when almost all the data are available will ensure
that p and the p value calculated after official unblinding
are similar. Changes to the statistical analysis plan after
the release of the high level result should not involve the
primary endpoint and any closely related secondary end-
points (e.g., endpoints that are components of a composite
primary endpoint). No alpha adjustment is necessary be-
cause there is no change to the conduct or to the analysis
of the ongoing trial. The proposal is not to be mistaken
for a futility analysis, which permits the early stopping of a
trial if the interim results are not promising [1].
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To make concrete how the timing of the analysis
might work, we continue with the global, event-driven,
endpoint-adjudicated trial. Suppose the trial design is
such that 500 events and a minimum follow-up of one
year are required. Assume that as the trial progresses it
becomes apparent that the 500th event will occur prior
to the completion of the minimum follow-up. A pro-
jection made around the time of the occurrence of the
400th adjudicated event suggests that the 500th
investigator-reported event (which is to be adjudi-
cated) will occur 4 months before the minimum
follow-up is complete. Suppose further that the con-
cordance between investigator-reported and endpoint
committee events is high [2]. Additional events may
occur between the occurrence of the adjudicated 500th
event and minimum follow-up which would be adjudi-
cated and included in the primary (official) analysis
but not included in the high level analysis.
Rather than wait for adjudication and the minimum
follow-up to be complete for all patients, suppose the
high level analysis is conducted soon after the occur-
rence of the investigator-reported 500th event. The ana-
lysis would include all adjudicated events, and
investigator-reported events would be included only for
events that are pending adjudication. While the focus is
on event-driven trials, the proposal may hold for visit-
driven trials as well if the time between the last patient
visit and database lock is long.
Two situations warrant additional consideration re-
garding timing. For the first consideration, the analysis
will need to occur later than when primary endpoint
data are available. If the patient follow-up for the pri-
mary endpoint is less than that for other endpoints, the
proposed analysis must occur closer to the time of the
final visit to prevent any modifications to the trial. For
the second consideration it may occur earlier. A few
stragglers can drag out the time to trial completion
either because of how late they enrolled or because their
actual final visit is known in advance to occur much
after the scheduled final visit. In such a case, the analysis
can occur sooner by excluding their final visit data, and
it assumes that the consequence of data omission is
expected to be minimal.
Benefit
Suppose the sponsor is told that p > p1. Then at-risk tasks
can stop or move at a slower pace. Sponsors will likely re-
allocate resources and other development areas will auto-
matically receive more attention. In all other respects, the
trial continues through completion. If instead the sponsor
is told that p ≤ p1, the at-risk tasks continue as per plan.
One possible objection to the proposal may be: Why
should anyone other than the sponsor care? After all, the
gain is merely related to operational efficiency. No ethical
or public health matters are at stake. The response to that
is twofold: (1) What is proposed is an option for sponsors
to consider. Currently, tradition mandates how to unblind
all late stage trials. Convention should guide, not dictate,
how trials should be run. For some sponsor organizations,
particularly ones with limited financial resources, the gain
can be substantial. It could be argued the gain in efficiency
could indirectly benefit public health since the limited
resources would be directed to other more promising
development programs. (2) A wider recognition of the
cost that the current system imposes itself has value.
Conclusion
Releasing the high level result earlier is not appropriate
for all trials: (1) A trial for which all data become avail-
able soon after the final visit is unlikely to be a good
candidate, and neither is (2) a trial in which the sponsor
will continue its at-risk tasks as planned even if p > p1
(because, say, of the importance of the secondary end-
points). One risk with the proposal is the possibility of
decline in the quality of data collected toward the end if
the sponsor is told that p > p1. While this is possible, it
seems unlikely, as the processes to see the trial through
to completion will have already been in place since the
start of the trial. Another risk might be if the informa-
tion that p > p1 is leaked and is in the public domain be-
fore official unblinding. This could complicate matters
for the sponsor if the external community reacts to the
result before the sponsor has had a chance to under-
stand the totality of the trial data. To avoid this risk, the
sponsor has to be committed to a disciplined approach
and judiciously choose the timing for release of such
information.
A press release may follow on the heels of a completed
trial. Whether this is to occur soon after limited early
unblinding will need to be thought through in advance.
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